Neon points to PFS, biomarkers as signs of neoantigen activity in single-arm combo trial

With Phase Ib data on its neoantigen cancer vaccine plus Opdivo announced Monday, Neon is the latest company to suggest its immuno-oncology candidate improves on the efficacy of checkpoint inhibitor alone by comparing a single-arm combination study to historical controls. The company cites the combo's effects on PFS across three

Read the full 509 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE